Ocular Diseases: Ingenia has focused to date on therapeutics targeting neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) markets. Ingenia’s products will compete with and/or compliment Standard of Care, Vascular Endothelial Growth Factor (VEGF) blockers currently on the market. Below are the key target ocular indications.

  • DME: The #1 cause of blindness in diabetic adults. The estimated G7 prevalent cases were ~5.9 million (2020), and the G7 annual sales for therapeutics were $3.2B (2019).
  • nAMD: The leading cause of vision loss among adults >50 years of age. The estimated G7 prevalent cases were ~3.5 million (2020), and the G7 annual sales for therapeutics were ~$6B (2019).
  • Retinal Vein Occlusion (RVO): Clots in the retina veins cause RVO, characterized by macular edema and neovascularization in the retina. The G7 prevalent cases were ~4.1million (2020).
  • Glaucoma: Glaucoma is the second leading cause of blindness worldwide, affecting approximately 99.7 million people (2020) with an expected increase to over 119.4 million people by 2028. The 2018 global annual sales for therapeutics were $6.59B.

Chronic Diseases: Ingenia is developing first-in-class therapeutic antibody candidates for undisclosed chronic diseases.